ABUS vs BDX · P/E 5.4, rev $6.2M vs P/E 34, rev $21.84B
Arbutus Biopharma Corp (ABUS) versus Becton Dickinson and Company (BDX) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Not investment advice. Open the ABUS and BDX stock pages for the full models.
Not investment advice.